ECSP12011968A - Nuevos compuestos tricíclicos - Google Patents
Nuevos compuestos tricíclicosInfo
- Publication number
- ECSP12011968A ECSP12011968A ECSP12011968A ECSP12011968A EC SP12011968 A ECSP12011968 A EC SP12011968A EC SP12011968 A ECSP12011968 A EC SP12011968A EC SP12011968 A ECSP12011968 A EC SP12011968A
- Authority
- EC
- Ecuador
- Prior art keywords
- tricyclic compounds
- new tricyclic
- compounds
- new
- prodrugs
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención proporciona un compuesto de fórmula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), Ii), (Ij), (Ik), o (Il), como se define en la presente, las sales farmacéuticamente aceptables, profármacos, metabolitos biológicamente activos, estereoisómeros e isómeros del mismo, en los que las variables se definen en la presente. Los compuestos de la invención son útiles para tratar enfermedades inmunológicas y oncológicas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26559109P | 2009-12-01 | 2009-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP12011968A true ECSP12011968A (es) | 2012-07-31 |
Family
ID=44115273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP12011968 ECSP12011968A (es) | 2009-12-01 | 2012-06-12 | Nuevos compuestos tricíclicos |
Country Status (20)
Country | Link |
---|---|
US (2) | US8785639B2 (es) |
EP (1) | EP2506713A4 (es) |
JP (1) | JP2013512282A (es) |
KR (1) | KR20120102724A (es) |
CN (1) | CN102711470A (es) |
AU (1) | AU2010326030A1 (es) |
CA (1) | CA2781010A1 (es) |
CL (1) | CL2012001396A1 (es) |
CR (1) | CR20120294A (es) |
DO (1) | DOP2012000149A (es) |
EC (1) | ECSP12011968A (es) |
GT (1) | GT201200167A (es) |
IL (1) | IL220053A0 (es) |
MX (1) | MX2012006381A (es) |
NZ (1) | NZ599938A (es) |
PE (1) | PE20130005A1 (es) |
RU (1) | RU2012127368A (es) |
SG (1) | SG181147A1 (es) |
WO (1) | WO2011068899A1 (es) |
ZA (1) | ZA201203588B (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102118968A (zh) | 2008-06-10 | 2011-07-06 | 雅培制药有限公司 | 新的三环化合物 |
US20100277320A1 (en) * | 2009-06-30 | 2010-11-04 | Gold Steven K | RFID Keypad Assemblies |
SI2506716T1 (sl) | 2009-12-01 | 2017-10-30 | Abb Vie Inc. | Nove triciklične spojine |
WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
AU2012244549B2 (en) | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
MY166970A (en) * | 2011-08-12 | 2018-07-26 | Nissan Chemical Ind Ltd | Subtituted pyrrolo [2,3-h][1,6]naphthyridines and compositions thereof as jak inhibitors |
CN102603743B (zh) * | 2012-02-24 | 2014-05-28 | 南京天易生物科技有限公司 | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 |
DK2861595T5 (en) | 2012-06-13 | 2018-01-15 | Incyte Holdings Corp | Substituted tricyclic compounds as FGFR inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014060113A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
EP2955181B1 (en) | 2013-02-08 | 2019-10-30 | Nissan Chemical Corporation | Tricyclic pyrrolopyridine compound, and jak inhibitor |
WO2014169473A1 (en) * | 2013-04-19 | 2014-10-23 | Abbvie Inc. | 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS |
MX367878B (es) | 2013-04-19 | 2019-09-10 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
MY182812A (en) * | 2014-05-14 | 2021-02-05 | Nissan Chemical Ind Ltd | Tricyclic compound and jak inhibitor |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EP3259269B9 (en) | 2015-02-20 | 2020-03-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
JP6589233B2 (ja) * | 2015-03-17 | 2019-10-16 | 株式会社カネカ | トリアリールメタノールの製造方法 |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN116270645A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
AU2017287762C1 (en) | 2016-06-30 | 2020-04-23 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
CR20190282A (es) | 2016-12-16 | 2019-08-21 | Janssen Pharmaceutica Nv | Inhibidores de moléculas pequeñas de la familia de quinasas jak |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3710431A4 (en) * | 2017-11-03 | 2021-07-07 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIMIDINE JAK INHIBITORS AND METHODS FOR THEIR MANUFACTURE AND USE |
EP3539966A1 (en) | 2018-03-12 | 2019-09-18 | AbbVie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
JP2021523118A (ja) | 2018-05-04 | 2021-09-02 | インサイト・コーポレイションIncyte Corporation | Fgfr阻害剤の塩 |
BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
TW202016110A (zh) * | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
CN108707101B (zh) * | 2018-07-05 | 2022-05-17 | 深圳大学 | 光催化合成生物碱的方法 |
JP7516365B2 (ja) * | 2018-10-23 | 2024-07-16 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規化合物 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
BR112022007163A2 (pt) | 2019-10-14 | 2022-08-23 | Incyte Corp | Heterociclos bicíclicos como inibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
IL293001A (en) | 2019-12-04 | 2022-07-01 | Incyte Corp | Derivatives of fgfr repressors |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN113620957B (zh) * | 2020-05-08 | 2022-04-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种胺甲基吡嗪类化合物的制备方法 |
US20230365544A1 (en) * | 2020-05-12 | 2023-11-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of calcium channel activity and uses thereof |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
CR20230057A (es) | 2020-07-02 | 2023-08-15 | Incyte Corp | Compuestos tríciclicos de urea como inhibidores de jak2 v617f |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1376A (en) * | 1839-10-18 | Wateb-wheel | ||
GB716327A (en) | 1951-09-05 | 1954-10-06 | Ici Ltd | New heterocyclic compounds |
US3663559A (en) | 1969-12-03 | 1972-05-16 | Union Carbide Corp | Preparation of oxo-furo-pyridines from furylvinyl isocyanates |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4053474A (en) | 1976-04-21 | 1977-10-11 | E. R. Squibb & Sons, Inc. | Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
EP0423805B1 (en) | 1989-10-20 | 2000-08-23 | Kyowa Hakko Kogyo Kabushiki Kaisha | Condensed purine derivatives |
BR9105935A (pt) | 1990-01-11 | 1992-11-17 | Isis Pharmaceuticals Inc | Composicao,analogo de oligonucleotideo,oligonucleotideo sequenciado misto,processo para a preparacao de nucleosideos 2'-substituidos,composicao para modular a atividade de rna,processos para modular a producao de uma proteina por um organismo,para tratar um animal,para detectar a presenca ou ausencia de rna,oligonucleotideo ou analogo de analogo de oligonucleotideo resistente a nuclease e processo para tratar um organismo tendo uma doenca |
US6262241B1 (en) | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
DE06001779T1 (de) | 1991-03-18 | 2010-01-14 | New York University | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
JP3147902B2 (ja) | 1991-06-14 | 2001-03-19 | ファルマシア・アンド・アップジョン・カンパニー | イミダゾ〔1,5−a〕キノキサリン |
US5212310A (en) | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
US5266698A (en) | 1992-04-30 | 1993-11-30 | Neurogen Corporation | Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands |
US5306819A (en) | 1992-08-27 | 1994-04-26 | Neurogen Corporation | Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5939419A (en) | 1993-02-26 | 1999-08-17 | Schering-Plough Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
US5736540A (en) | 1993-07-29 | 1998-04-07 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US5733905A (en) | 1993-07-29 | 1998-03-31 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US5547975A (en) | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
US5763137A (en) | 1995-08-04 | 1998-06-09 | Agfa-Gevaert, N.V. | Method for making a lithographic printing plate |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
DE69940808D1 (de) | 1998-03-04 | 2009-06-10 | Bristol Myers Squibb Co | Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren |
IL139197A0 (en) | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
EP1325006A2 (en) | 2000-08-07 | 2003-07-09 | Neurogen Corporation | Heterocyclic compounds as ligands of the gaba a? receptor |
GB0124299D0 (en) | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
US20040127492A1 (en) | 2002-02-19 | 2004-07-01 | Pharmacia Corporation | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20060074102A1 (en) * | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
ES2341559T3 (es) | 2004-07-23 | 2010-06-22 | The Medicines Company (Leipzig) Gmbh | Pirido(3',2':4,5)tieno(3,2-d)pirimidinas y pirido(3',2':4,5)furo(3,2-d)pirimidinas sustituidas para su utilizacion como inhibidores de la liberacion de pda-4 y/o tnf-alfa. |
CA2594422A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as cell cycle kinase inhibitors |
US7947695B2 (en) | 2005-01-14 | 2011-05-24 | Janssen Pharmaceutica Nv | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
US20060183758A1 (en) | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
US7593820B2 (en) | 2005-05-12 | 2009-09-22 | Cytopia Research Pty Ltd | Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof |
CN102127078A (zh) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
JP5071374B2 (ja) * | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ3阻害剤 |
EP1919924A2 (en) | 2005-08-16 | 2008-05-14 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
EP1937683A4 (en) | 2005-09-23 | 2010-08-25 | Coley Pharm Group Inc | PROCESS FOR 1H-IMIDAZO [4,5-C] PYRIDINES AND ANALOGUE THEREOF |
US7772231B2 (en) | 2005-12-29 | 2010-08-10 | Abbott Laboratories | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors |
WO2008063287A2 (en) | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
KR20090106604A (ko) * | 2007-01-12 | 2009-10-09 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 피리딘 화합물 |
JP2010532312A (ja) | 2007-01-30 | 2010-10-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 1−h−ピラゾロ(3,4b)ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用 |
WO2008112695A2 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
US7691869B2 (en) | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
US8188083B2 (en) * | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
CA2713710A1 (en) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
EP2247595B1 (en) | 2008-02-25 | 2011-07-20 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
EP2250172B1 (en) | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
CN102118968A (zh) * | 2008-06-10 | 2011-07-06 | 雅培制药有限公司 | 新的三环化合物 |
CN102143746A (zh) | 2008-07-03 | 2011-08-03 | 埃克塞利希斯股份有限公司 | Cdk 调节剂 |
CA2758359A1 (en) | 2009-04-14 | 2010-10-21 | Astellas Pharma Inc. | Fused pyrrolopyridine derivative |
US8361962B2 (en) * | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
SI2506716T1 (sl) | 2009-12-01 | 2017-10-30 | Abb Vie Inc. | Nove triciklične spojine |
WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
WO2013043826A1 (en) | 2011-09-21 | 2013-03-28 | Abbvie Inc. | Tricyclic compounds useful as protein kinase inhibitors |
-
2010
- 2010-12-01 RU RU2012127368/04A patent/RU2012127368A/ru not_active Application Discontinuation
- 2010-12-01 AU AU2010326030A patent/AU2010326030A1/en not_active Abandoned
- 2010-12-01 SG SG2012039905A patent/SG181147A1/en unknown
- 2010-12-01 JP JP2012542166A patent/JP2013512282A/ja active Pending
- 2010-12-01 NZ NZ599938A patent/NZ599938A/en not_active IP Right Cessation
- 2010-12-01 KR KR1020127016419A patent/KR20120102724A/ko not_active Application Discontinuation
- 2010-12-01 US US12/958,291 patent/US8785639B2/en active Active
- 2010-12-01 EP EP10835075.2A patent/EP2506713A4/en not_active Withdrawn
- 2010-12-01 PE PE2012000736A patent/PE20130005A1/es not_active Application Discontinuation
- 2010-12-01 WO PCT/US2010/058598 patent/WO2011068899A1/en active Application Filing
- 2010-12-01 MX MX2012006381A patent/MX2012006381A/es not_active Application Discontinuation
- 2010-12-01 CA CA2781010A patent/CA2781010A1/en not_active Abandoned
- 2010-12-01 CN CN2010800629352A patent/CN102711470A/zh active Pending
-
2012
- 2012-05-16 ZA ZA2012/03588A patent/ZA201203588B/en unknown
- 2012-05-29 IL IL220053A patent/IL220053A0/en unknown
- 2012-05-30 DO DO2012000149A patent/DOP2012000149A/es unknown
- 2012-05-30 CR CR20120294A patent/CR20120294A/es unknown
- 2012-05-30 GT GT201200167A patent/GT201200167A/es unknown
- 2012-05-30 CL CL2012001396A patent/CL2012001396A1/es unknown
- 2012-06-12 EC ECSP12011968 patent/ECSP12011968A/es unknown
-
2014
- 2014-06-09 US US14/299,652 patent/US20140349970A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA201203588B (en) | 2015-07-29 |
PE20130005A1 (es) | 2013-02-16 |
SG181147A1 (en) | 2012-07-30 |
US20110190489A1 (en) | 2011-08-04 |
KR20120102724A (ko) | 2012-09-18 |
EP2506713A1 (en) | 2012-10-10 |
AU2010326030A1 (en) | 2012-06-07 |
NZ599938A (en) | 2014-08-29 |
GT201200167A (es) | 2014-06-10 |
CA2781010A1 (en) | 2011-06-09 |
CN102711470A (zh) | 2012-10-03 |
CL2012001396A1 (es) | 2012-09-14 |
DOP2012000149A (es) | 2012-09-30 |
WO2011068899A1 (en) | 2011-06-09 |
IL220053A0 (en) | 2012-10-31 |
JP2013512282A (ja) | 2013-04-11 |
EP2506713A4 (en) | 2014-09-03 |
MX2012006381A (es) | 2012-06-19 |
RU2012127368A (ru) | 2014-01-10 |
US8785639B2 (en) | 2014-07-22 |
US20140349970A1 (en) | 2014-11-27 |
CR20120294A (es) | 2012-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12011968A (es) | Nuevos compuestos tricíclicos | |
UY33071A (es) | Nuevos compuestos tricíclicos | |
CR20160007A (es) | Nuevos compuestos triciclicos | |
UY35630A (es) | Carboxamidas primarias como inhibidores de btk | |
CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
CR20130500A (es) | Moduladores de los receptores de hormonas nucleares | |
CU20110235A7 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
UY34959A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
ECSP11011079A (es) | Nuevos compuestos de hidroxiareno. | |
UY34960A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
ECSP11011485A (es) | Espiro-epóxidos como productos intermedios. | |
ECSP13013026A (es) | Isoxazolinas como agentes terapéuticos | |
UY33176A (es) | Derivados de oxazolopirimidina sustituida en 2, 5, 7. | |
ECSP13012495A (es) | Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina | |
UY36628A (es) | Indazolonas como moduladores de la señalización de tnf | |
CR20150272A (es) | Derivado de hidantoina | |
UY35223A (es) | Moduladores heterocíclicos de receptores de hormonas nucleares | |
CR20150148A (es) | Azaindolinas | |
CO6460762A2 (es) | 5-alquinil-piridinas | |
UY33179A (es) | Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2,5-sustituido. | |
UY35014A (es) | Moduladores heterocíclicos de los receptores de hormonas nucleares | |
AR073708A1 (es) | Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen | |
UY31931A (es) | Compuestos de diarilo y uso de los mismos | |
CO6592046A2 (es) | 5-alquinil pirimidas y su uso como inhibidores de quinasa | |
ECSP11011464A (es) | Tia-triaza-ciclopentazulenos |